Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Dec 17, 2025
- Closes
- Sep 7, 2026 (in 53 days)
- Last verified
- Jul 16, 2026
Classification and identifiers
- Solicitation number
- PAR-25-039
- Assistance listing (CFDA)
- 93.242
Amount
Amount not published by the funder
Who can apply
Local government agencies, Public colleges and universities, State government agencies, Small businesses, and Private colleges and universities can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this opportunity
Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts.